Skip to main content

Advertisement

Table 6 Plasma pharmacodynamics in MAD cohort

From: Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

  Placebo MAD2 MAD3 MAD4
Plasma Aβ(1-40) mean (SD) concentration (pg/mL)
Maximal % change from baseline -27.39 (48.98) 15.92 (97.17) 39.71 (17.91) 120.71 (53.21)
24 h post final dose 13.42 (28.09) 16.99a 17.50 (9.14) 86.20 (48.06)
  1. Percentage change from baseline in Aβ (1-40)
  2. amyloid β, MAD multiple ascending dose
  3. aInsufficient “n” to calculate SD